About the Company
The Takeda Pharmaceutical Company Limited (武田薬品工業株式会社, Takeda Yakuhin Kōgyō kabushiki gaisha) [takeꜜda jakɯçiŋ koꜜːɡʲoː] is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following its merger with Shire). The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.
Sector
Industrial Applications and Services
Industry
Services-Offices & Clinics of Doctors of Medicine
Employees
277
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Oncology Institute, Inc.
The Oncology Institute, Inc. (NASDAQ:TOI) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 13, 2025 The Oncology Institute, Inc. misses on earnings expectations. Reported EPS ...
The Oncology Institute Inc (TOI) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...
The Oncology Institute Inc (TOI) reports over 20% revenue growth and significant contract expansions, while navigating EBITDA ...
Oncology Institute Shares Drop 7% as Earnings Miss Despite Revenue Growth
The Oncology Institute, Inc. (NASDAQ:TOI) saw its shares fall 7.07% in pre-market trading Thursday after reporting ...
The Oncology Institute, Inc. to Release Q2 2025 Financial ... - Nasdaq
The Oncology Institute, Inc. (TOI) announced that it will release its financial results for the second quarter of 2025 on August 13, 2025, after market close, followed by a conference call at 5:00 ...
The Oncology Institute Announces Changes to Board of Directors
Richard Barasch to Retire; Anne McGeorge Brings Extensive Financial Experience to Role as New ChairmanCERRITOS, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: ...
The Oncology Institute, Inc. Announces $16.5 Million Private ... - Nasdaq
The Oncology Institute, Inc. has announced a private placement agreement with accredited investors that is anticipated to yield approximately $16.5 million in gross proceeds.
The Oncology Institute shares tumble 7% as earnings miss overshadows revenue beat
The value-based community oncology group reported a second quarter loss of $0.15 per share, missing analyst estimates of a $0.09 loss by $0.06. Revenue came in at $119.8 million, surpassing the ...
The Oncology Institute Reports Second Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance
CERRITOS, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, ...
The Oncology Institute, Inc. (NASDAQ:TOI) Q3 2024 Earnings Call ...
The Oncology Institute, Inc. (NASDAQ:TOI) Q3 2024 Earnings Call Transcript Published on November 15, 2024 at 8:18 am by Insider Monkey Transcripts in News, Transcripts ...
The Oncology Institute, Inc. (TOI): Among Stocks Insiders Were Buying ...
The Oncology Institute, Inc. (NASDAQ: TOI) Market Cap: $100.05 million Number of insiders buying: 8 The Oncology Institute ranks tenth among the 20 stocks that insiders are buying in Q1 2025.
The Oncology Institute, Inc. (TOI) Q3 2023 Earnings Call Transcript
The Oncology Institute, Inc. (NASDAQ: TOI) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Dan Virnich - Chief Executive Officer ...
The Oncology Institute, Inc. (TOI) Q2 2024 Earnings Call Transcript
The Oncology Institute, Inc. (NASDAQ: TOI) Q2 2024 Earnings Conference Call August 13, 2024 5:00 PM ET Company Participants Mark Hueppelsheuser – General Counsel Dan Virnich – Chief Executive ...
Similar Companies
| Company | Ticker | 90 Days Forecast | Market Cap. (USD M) | P/E | P/B |
|---|---|---|---|---|---|
| Airsculpt Technologies, Inc. | AIRS | Predict | 390.54 | -68.82 | 4.28 |
| Hims & Hers Health, Inc. | HIMS | Predict | 945.54 | -14.34 | 2.89 |
| LifeMD, Inc. | LFMD | Predict | -62.12 | 0.00 | -205.89 |
| LifeMD, Inc. | LFMDP | Predict | -231.87 | 0.00 | -456.68 |
| SBC Medical Group Holdings Inc | SBC | Predict | 568.83 | None | 2.51 |
| SBC Medical Group Holdings Inc | SBCWW | Predict | 26.79 | None | 0.13 |
| Teladoc Health, Inc. | TDOC | Predict | 1328.09 | -1.77 | 0.93 |
| Oncology Institute, Inc. | TOI | Predict | 313.03 | -0.28 | 61.75 |
| Oncology Institute, Inc. | TOIIW | Predict | 2.27 | None | 0.15 |
Loading the latest forecasts...